Consenso del Grupo Latinoamericano de estudio de Mieloma Múltiple (MM) GELAMM para el manejo del MM en estado de Pandemia SARS CoV-2 / COVID 19

Abstract

COVID-19 disease was detected at the end of 2019 in Wuhan, China. Due it´s quickly spread was declared a health emergency initially and after identifying cases outside China with indigenous transmission, characterized by considerably high mortality in countries such as Italy and Spain, it was declared a pandemic by the World Health Organization. It has been shown that older patients with a history of chronic diseases including cancer develop severe disease, presenting a higher risk of mortality from SARS-CoV2 / COVID-19. This is especially important in the handle of patients with Multiple Myeloma (MM), generating new challenges, improvement and learning opportunities for Medical group, that contribute to the risk-benefit analysis of immunosuppressive treatment for this type of pathology. The consensus aims to provide guidance for the management of patients with MM in this time where the health professional requires information to carry out efficient therapies in patient care.